Enforma contests FTC allegations
This article was originally published in The Tan Sheet
Executive Summary
Pointing to 19 studies as evidence of its Chitozyme weight-loss supplement's efficacy, company says FTC's recent contempt motion is "frivolous" and commission will be unable to provide clear and convincing evidence that Enforma lacks adequate substantiation for its ad claims. Enforma asserts FTC is using an undefined standard for "competent and reliable scientific evidence" and suggests commission should clarify this standard by telling Enforma what studies it considers vital to marketing Chitozyme. Firm says it has turned over to FTC studies on Carb Trapper Plus, and notes its products carry money-back guarantees, thereby refuting FTC's claim that consumers have suffered financial harm (1"The Tan Sheet" Aug. 5, 2002, p. 5). Enforma says it is considering suing FTC if company prevails in present action. Hearing on FTC's contempt motion, preliminary injunction request is scheduled for Sept. 30...
You may also be interested in...
Enforma Carb Trapper Plus Supplement Ad Claims Under FTC Scrutiny
Enforma Natural Products could be hit with civil contempt charges for the third time if FTC determines the firm is making unsubstantiated advertising and marketing claims for its Carb Trapper Plus weight-loss product
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.